Jean-Charles Soria, Amgen’s senior vice president of Oncology within Global Development, shared an article on LinkedIn:
“Liquid biopsies in CRC
Serial MRD monitoring:
- Detects recurrence 8–11 months earlier than imaging
- Improves sensitivity from 40–50% to 80–90%
- Helps monitor ACT response
Liquid tumor-agnostic assays are evolving: now integrating
- Methylation
- Fragmentomics
- Mutations.”
Title: Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
Authors: B. Martínez-Castedo, D.G. Camblor, J. Martín-Arana, J.A. Carbonell-Asins, B. García-Micó, V. Gambardella, M. Huerta, S. Roselló, D. Roda, F. Gimeno-Valiente, A. Cervantes, N. Tarazona
Read the Full Article.
More posts featuring Jean-Charles Soria.
